Blood- and tissue-based tumor genomics: a battle royale or match made in heaven?

Barata et al. [1] provided the first analysis of genomic alterations (GAs) identified by matched circulating tumor DNA (ctDNA) and tumor tissue next-generation sequencing (NGS) platforms in patients with advanced urothelial carcinoma (UC). When controlling for GAs screened by both platforms, the authors reported low concordance between ctDNA and tissue NGS (16.4%). The discordance observed, between ctDNA and tissue NGS, may reflect their potential complementarity leading to improved detection of GAs and revealing the dynamics of tumor genomic heterogeneity.

http://ift.tt/2fPwqfd